logo

TSVT(Delisted)

2seventy bioยทNASDAQ
--
--(--)

TSVT Profile

2seventy Bio, Inc.

A leading immuno-oncology cell therapy company that develops gene,cell therapies and oncology roots for cancer and severe genetic diseases

--
04/26/2021
11/05/2021
NASDAQ Stock Exchange
65
12-31
Common stock
60 Binney Street , Cambridge , Massachusetts 02142
--
2seventy bio, Inc., was incorporated in Delaware on April 26, 2021. The company is a cell and gene therapy company focused on the research, development and commercialization of cancer translational therapies. The company is advancing several preclinical and clinical programs in oncology and, together with their partner Bristol-Myers Squibb (Bristol-Myers Squibb), is providing Abecma, including immunomodulators, proteasome inhibitors and anti-CD38 monoclonal antibodies, to multiple myeloma patients in the United States after approval for at least four prior treatments.